Publication | Open Access
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
110
Citations
36
References
2023
Year
The results reported in this first real-world analysis mostly confirmed the results achieved in the TOPAZ-1 trial in terms of PFS, ORR and safety.
| Year | Citations | |
|---|---|---|
Page 1
Page 1